DiaMedica Therapeutics Inc. (DMAC) Earnings History
Net Loss22 years of earnings data (2004–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
DiaMedica Therapeutics Inc. (DMAC) Earnings Overview
As of June 22, 2026, DiaMedica Therapeutics Inc. (DMAC) reported trailing twelve-month net income of -$35M, reflecting -16.7% year-over-year growth. The company earned $-0.65 per diluted share over the past four quarters.
Looking at the long-term picture, DMAC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$210,602 in fiscal 2005.
DiaMedica Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATHA (-$129M net income), ACMR ($91M net income, 10.4% margin), NERV (-$415M net income), DMAC has comparable earnings metrics. Compare DMAC vs ATHA →
DMAC Earnings vs Peers
Earnings metrics vs comparable public companies
DMAC Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$33M | -34.0% | -$34M | $-0.70 | - | - |
| 2024 | -$24M | -26.1% | -$27M | $-0.60 | - | - |
| 2023 | -$19M | -41.7% | -$21M | $-0.60 | - | - |
| 2022 | -$14M | -0.6% | -$14M | $-0.52 | - | - |
| 2021 | -$14M | -10.6% | -$14M | $-0.65 | - | - |
| 2020 | -$12M | -15.4% | -$13M | $-0.78 | - | - |
| 2019 | -$11M | -85.7% | -$12M | $-0.89 | - | - |
| 2018 | -$6M | -34.6% | -$7M | $-0.74 | -1146.8% | -1352.2% |
| 2017 | -$4M | -91.6% | -$5M | $-0.72 | - | - |
| 2016 | -$2M | -54.1% | -$2M | $-0.47 | - | - |
| 2015 | -$1M | +70.1% | -$1M | $-0.40 | - | - |
| 2014 | -$5M | +35.0% | -$5M | $-1.55 | - | - |
| 2013 | -$7M | +26.3% | -$7M | $-2.71 | - | - |
| 2012 | -$10M | -52.1% | -$10M | $-4.11 | - | - |
| 2011 | -$7M | -54.9% | -$7M | $-2.93 | - | - |
| 2010 | -$4M | -75.2% | -$4M | $-2.98 | - | - |
| 2009 | -$2M | -31.4% | -$2M | $-2.54 | - | - |
| 2008 | -$2M | +20.6% | -$2M | $-2.04 | - | - |
| 2007 | -$2M | -199.9% | -$2M | $-2.91 | -1452.8% | -1438.0% |
| 2006 | $-778,018 | -269.4% | $-787,211 | $-0.89 | -3023.0% | -3058.7% |
| 2005 | $-210,602 | +67.1% | $-203,007 | $-0.24 | -820.1% | -790.6% |
| 2004 | $-640,020 | - | $-603,433 | $-0.02 | -1889.0% | -1781.0% |
Download Data
Export DMAC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DMAC — Frequently Asked Questions
Quick answers to the most common questions about buying DMAC stock.
What is DMAC earnings per share (EPS)?
DMAC trailing twelve-month (TTM) diluted EPS is $-0.65, reflecting -16.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2004 to 2025 is available in the table on this page.
What is DiaMedica Therapeutics Inc.'s net income?
DiaMedica Therapeutics Inc. (DMAC) trailing twelve-month net income is $-35M as of 2025. Earnings declined -16.7% year-over-year.
Is DMAC profitable?
DMAC is not currently profitable on a TTM basis, reporting a net loss of $-35M. Net margin is N/A. Investors should monitor for a return to profitability.
What is DMAC's earnings growth rate?
DMAC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2004 to 2025.
What are DMAC's profit margins?
DiaMedica Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -67.7%.
Is DMAC growing earnings?
DMAC earnings are declining — EPS fell -16.7% year-over-year. TTM net income dropped to $-35M. This contrasts with the 5-year CAGR of N/A.
What was DMAC's best earnings year?
DiaMedica Therapeutics Inc.'s highest annual net income on record is $-210602.00, achieved in fiscal year 2005. Earnings history on this page spans 2004 to 2025 and includes all annual and quarterly figures.
What were DMAC's earnings last quarter?
DMAC's most recent reported quarter was Q1 2026. Net income was $-10M with diluted EPS of $-0.19. For a full breakdown of all quarters, see the quarterly earnings table on this page.